Motor neuron diseases are a group of progressive and ultimately fatal neurodegenerative disorders of the motor system, ...

Published today in Frontiers in Neuroscience, the study fundamentally alters brain and nervous system medicine-giving doctors new clues as to why patients with motor neuron disease, multiple sclerosis ...

HYNR-CS-Allo is under clinical development by Corestemchemon and currently in Phase I for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, ...

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal motor neuron degenerative disease characterised by ... cell death and modulation of stress granule formation across multiple stress ...

CNMAU-8 is under clinical development by Clene and currently in Phase III for Relapsing Multiple Sclerosis (RMS). According to GlobalData, Phase III drugs for Relapsing Multiple Sclerosis (RMS) have ...

In PSP, there is gross midbrain atrophy and neuronal loss, gliosis and abundant neurofibrillary tangles and neuropil threads in many brain regions. There is a uniform presence of tau-positive ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

in a relevant discipline Amyotrophic lateral sclerosis (ALS)—the commonest type of motor neuron disease (MND)—is a rapidly progressive paralysing illness of mid-adulthood. It has a lifetime risk of ~1 ...

In immunotherapy trials, MRI volume loss does not correlate with degeneration. It does correlate with removal ... Anti-inflammatory treatments for multiple sclerosis initially shrink the brain, too, ...

Aug. 23, 2024 — A collaborative investigation among experts in Alzheimer's disease and multiple sclerosis (MS) finds evidence that MS patients are less likely to have amyloid plaques ...